收费全文 | 52143篇 |
免费 | 5671篇 |
国内免费 | 89篇 |
耳鼻咽喉 | 437篇 |
儿科学 | 1556篇 |
妇产科学 | 1164篇 |
基础医学 | 7249篇 |
口腔科学 | 1331篇 |
临床医学 | 6528篇 |
内科学 | 10102篇 |
皮肤病学 | 823篇 |
神经病学 | 4343篇 |
特种医学 | 2005篇 |
外国民族医学 | 1篇 |
外科学 | 6663篇 |
综合类 | 1211篇 |
一般理论 | 36篇 |
预防医学 | 6109篇 |
眼科学 | 998篇 |
药学 | 4225篇 |
中国医学 | 100篇 |
肿瘤学 | 3022篇 |
2022年 | 383篇 |
2021年 | 786篇 |
2020年 | 515篇 |
2019年 | 832篇 |
2018年 | 911篇 |
2017年 | 664篇 |
2016年 | 782篇 |
2015年 | 890篇 |
2014年 | 1228篇 |
2013年 | 1735篇 |
2012年 | 2571篇 |
2011年 | 2553篇 |
2010年 | 1439篇 |
2009年 | 1406篇 |
2008年 | 2412篇 |
2007年 | 2480篇 |
2006年 | 2421篇 |
2005年 | 2309篇 |
2004年 | 2183篇 |
2003年 | 2092篇 |
2002年 | 1999篇 |
2001年 | 1597篇 |
2000年 | 1495篇 |
1999年 | 1522篇 |
1998年 | 670篇 |
1997年 | 531篇 |
1996年 | 514篇 |
1995年 | 532篇 |
1994年 | 476篇 |
1993年 | 517篇 |
1992年 | 1242篇 |
1991年 | 1154篇 |
1990年 | 1103篇 |
1989年 | 1064篇 |
1988年 | 985篇 |
1987年 | 982篇 |
1986年 | 990篇 |
1985年 | 919篇 |
1984年 | 797篇 |
1983年 | 649篇 |
1982年 | 448篇 |
1981年 | 368篇 |
1979年 | 595篇 |
1978年 | 499篇 |
1977年 | 379篇 |
1976年 | 389篇 |
1974年 | 441篇 |
1973年 | 418篇 |
1972年 | 405篇 |
1969年 | 367篇 |
Objective
Comparative survival between neoadjuvant chemotherapy and adjuvant chemotherapy for patients with cT2-4N0-1M0 non–small cell lung cancer has not been extensively studied.Methods
Patients with cT2-4N0-1M0 non–small cell lung cancer who received platinum-based chemotherapy were retrospectively identified. Exclusion criteria included stage IV disease, induction radiotherapy, and targeted therapy. The primary end point was disease-free survival. Secondary end points were overall survival, chemotherapy tolerance, and ability of Response Evaluation Criteria In Solid Tumors response to predict survival. Survival was estimated using the Kaplan–Meier method, compared using the log-rank test and Cox proportional hazards models, and stratified using matched pairs after propensity score matching.Results
In total, 330 patients met the inclusion criteria (n = 92/group after propensity-score matching; median follow-up, 42 months). Five-year disease-free survival was 49% (95% confidence interval, 39-61) for neoadjuvant chemotherapy versus 48% (95% confidence interval, 38-61) for adjuvant chemotherapy (P = .70). On multivariable analysis, disease-free survival was not associated with neoadjuvant chemotherapy or adjuvant chemotherapy (hazard ratio, 1.1; 95% confidence interval, 0.64-1.90; P = .737), nor was overall survival (hazard ratio, 1.21; 95% confidence interval, 0.63-2.30; P = .572). The neoadjuvant chemotherapy group was more likely to receive full doses and cycles of chemotherapy (P = .014/0.005) and had fewer grade 3 or greater toxicities (P = .001). Response Evaluation Criteria In Solid Tumors response to neoadjuvant chemotherapy was associated with disease-free survival (P = .035); 15% of patients receiving neoadjuvant chemotherapy (14/92) had a major pathologic response.Conclusions
Timing of chemotherapy, before or after surgery, is not associated with an improvement in overall or disease-free survival among patients with cT2-4N0-1M0 non–small cell lung cancer who undergo complete surgical resection. 相似文献Methods: A retrospective analysis was performed to identify patients with isolated PCL injuries that underwent reconstruction between 2001 and 2014. Patients with multi-ligamentous injury or another concomitant knee pathology were excluded. Medical records were reviewed for demographic, clinical and operative data. Patients were contacted for administration of a telephone-based questionnaire which included the International Knee Documentation Committee (IKDC) Subjective Knee Evaluation form, Lysholm-Tegner scales, Marx activity scale (MAS), return to sport status, and patient satisfaction instruments.
Results: A total of 15 isolated PCL reconstructions in 14 patients with a mean age of 27.5 years (range 17–43) met the study inclusion criteria; mean follow up was 6.3 years (range 1.4–15.2). Pre-operatively, the primary complaint was knee instability in all patients; on physical examination, lack of a firm end point during posterior drawer testing was found in 93% (14/15) of the knees. In total, 12 of 15 knees underwent transtibial, single-bundle PCLR and three of 15 underwent tibial inlay, double bundle PCLR. Graft types included: quadriceps autograft (7/15), Achilles allograft (6/15), and hamstring autograft (2/15). There were no graft failures in our patient cohort. At most recent follow up the mean scores respectively on the IKDC form, Lysholm-Tegner scales and MAS were (standard deviation): 77.3 (16.5), 83.1 (17.9), 6.13 (2.6), and 7.1 (6.0). All fourteen patients were athletes prior to their injury and 79% (11/14) returned to sport and overall patient satisfaction was 9.2/10.
Conclusions: Isolated PCLR provides good outcomes at mean medium-term follow up with restoration of function, high rate of return to sport and overall patient satisfaction. 相似文献